Elaine Sophie Elizabeth Stokes
AstraZeneca
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Elaine Sophie Elizabeth Stokes.
Tetrahedron Letters | 2000
Christopher D. Davies; Stephen P. Marsden; Elaine Sophie Elizabeth Stokes
Vinyl dioxazaborocines 5 with asymmetric centres on the nitrogen bridgehead substituent have been prepared and assayed in nitrile oxide and nitrone cycloadditions, giving asymmetric inductions of up to 70 and 74% ee, respectively.
Tetrahedron Letters | 1998
Christopher D. Davies; Stephen P. Marsden; Elaine Sophie Elizabeth Stokes
Abstract Vinyl dioxazaborocines 1a-c have been subjected to 1,3-dipolar cycloadditions with benzonitrile oxide. The products are enantiomerically enriched 5-substituted Δ 2 -isoxazolines 2a-c .
Bioorganic & Medicinal Chemistry Letters | 2008
David M. Andrews; Elaine Sophie Elizabeth Stokes; Greg R. Carr; Zbigniew Stanley Matusiak; Craig A. Roberts; Michael J. Waring; Madeleine C. Brady; Christine M. Chresta; Simon J. East
A lead benzamide, 3, was identified as a potent and low molecular weight histone deacetylase (HDAC) inhibitor. Optimization led to 16d, demonstrating an excellent balance of efficacy and non-efficacy properties, along with very desirable in vivo DMPK. The final compounds presented are >1000-fold more potent than the initial screen hit, an improvement in potency which was achieved with a concomitant significant improvement in all the main non-efficacy properties.
Bioorganic & Medicinal Chemistry Letters | 2008
David M. Andrews; Keith M. Gibson; Mark A. Graham; Zbigniew Stanley Matusiak; Craig A. Roberts; Elaine Sophie Elizabeth Stokes; Madeleine C. Brady; Christine M. Chresta
A lead benzamide, bearing a cyanopyridyl moiety (3), was identified as a potent and low molecular weight histone deacetylase (HDAC) inhibitor. Various replacements of the cyano group were explored at the C3-position, along with the exploration of solubility-enhancing groups at the C5-position. It was determined that cyano substitution at the C3-position of the pyridyl core, along with a methylazetidinyl substituent at the C5-position yielded optimal HDAC1 inhibition and anti-proliferative activity in HCT-116 cells.
Cancer Research | 2002
Stephen R. Wedge; Donald J. Ogilvie; Michael Dukes; Jane Kendrew; Rosemary Chester; Janet A. Jackson; Sarah J. Boffey; Paula J. Valentine; Jon Owen Curwen; Helen Musgrove; George A. Graham; Gareth Hughes; Andrew Peter Thomas; Elaine Sophie Elizabeth Stokes; Brenda Curry; Graham Richmond; Peter F. Wadsworth; Alison L. Bigley; Laurent Francois Andre Hennequin
Journal of Medicinal Chemistry | 2002
Laurent Francois Andre Hennequin; Elaine Sophie Elizabeth Stokes; Andrew Peter Thomas; Craig Johnstone; Patrick Ple; Donald J. Ogilvie; Michael Dukes; Stephen R. Wedge; Jane Kendrew; Jon Owen Curwen
Journal of Medicinal Chemistry | 1999
Laurent Francois Andre Hennequin; Andrew Peter Thomas; Craig Johnstone; Elaine Sophie Elizabeth Stokes; Patrick Ple; Jean-Jacques Marcel Lohmann; Donald J. Ogilvie; Mike Dukes; Steve R. Wedge; Jon Owen Curwen; and Jane Kendrew; Christine Lambert-van der Brempt
Archive | 1997
Andrew Peter Thomas; Craig Johnstone; Edward Clayton; Elaine Sophie Elizabeth Stokes; Jean-Jacques Marcel Lohmann; Laurent Francois Andre Hennequin
Cancer Research | 2000
Stephen R. Wedge; Donald J. Ogilvie; Michael Dukes; Jane Kendrew; Jon Owen Curwen; Laurent Francois Andre Hennequin; Andrew Peter Thomas; Elaine Sophie Elizabeth Stokes; Brenda Curry; Graham Richmond; Peter F. Wadsworth
Archive | 2000
Elaine Sophie Elizabeth Stokes; Darren Mckerrecher; Laurent Francois Andre Hennequin; Patrick Ple